SCHEMBL1636288

SCHEMBL1636288

CCOC(=O)c1n[nH]c2ccc(N3CCCNCC3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
POLB P06746 1/20 0.42
WNT1 P04628 3/20 0.42
DYRK1A Q13627 3/20 0.42
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CHRNB2 P17787 5/20 0.40
CHRNA4 P43681 5/20 0.40
RAB9A P51151 4/20 0.40
ALDH1A1 P00352 2/20 0.40
FLT3 P36888 1/20 0.40
NPC1 O15118 3/20 0.39
TP53 P04637 3/20 0.39
HSD17B10 Q99714 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14699196 0.82 KDM4E (0.57) KDM4EPOLBWNT1DYRK1ASIRT2
SCHEMBL64895 0.76 HPGD (0.51) SIRT2SIRT1NPSR1CHRNB2CHRNA4
SCHEMBL22708174 0.76 KDM4E (0.52) KDM4EPOLBNPSR1RAB9AALDH1A1
SCHEMBL492277 0.75 ADRB1 (0.40) KDM4ESIRT2SIRT1ALDH1A1TP53
SCHEMBL4101185 0.73 KDM4E (0.68) KDM4EPOLBRAB9AALDH1A1NPC1
SCHEMBL28503428 0.73 ADRB1 (0.40) POLBALDH1A1
SCHEMBL960087 0.72 KDM4E (0.66) KDM4EPOLBRAB9AALDH1A1NPC1
SCHEMBL5922444 0.72 KDM4E (0.66) KDM4EPOLBRAB9AALDH1A1NPC1
SCHEMBL1636035 0.72 KDM4E (0.66) KDM4EPOLBRAB9AALDH1A1NPC1
SCHEMBL5945683 0.71 MEN1 (0.58) KDM4EPOLBWNT1DYRK1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932248-B2 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity MEMORY PHARMACEUTICALS CORPORATION (US) 2011-04-26 US disclosed
EP-1963332-A1 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2008-09-03 EP disclosed
US-20070135417-A1 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity MEMORY PHARMACEUTICALS CORPORATION 2007-06-14 US disclosed
WO-2007056582-A1 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135417-A1 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity CHRNA7, CHRNA5, CHRNA3 KDM4E 4040/4885POLB 2942/4885WNT1 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.